These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

821 related items for PubMed ID: 12847592

  • 1. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M, Erturk D.
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [Abstract] [Full Text] [Related]

  • 2. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 3. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 4. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [Abstract] [Full Text] [Related]

  • 5. [Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer].
    Miyamoto H, Kawakami Y, Arimoto T, Asakawa M, Suzuki A, Fujikane T, Onodera S, Nakabayashi T, Yasuda S, Shimizu T.
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1127-34. PubMed ID: 1647149
    [Abstract] [Full Text] [Related]

  • 6. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

  • 7. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A, Ueoka H, Kiura K, Tabata M, Sunami K, Katayama Y, Yamane H, Hiraki A, Harada M.
    Anticancer Res; 1999 Feb; 19(1B):693-8. PubMed ID: 10216478
    [Abstract] [Full Text] [Related]

  • 8. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R.
    Anticancer Res; 1991 Feb; 11(2):681-4. PubMed ID: 1648333
    [Abstract] [Full Text] [Related]

  • 9. [A combination chemotherapy consisting of vincristine, etoposide and cyclophosphamide (VEC) for small cell carcinoma of the lung].
    Adachi K, Ogawa M, Inagaki J, Horikoshi N, Inoue K, Ikeda K, Usui N, Nakata H, Tada A, Aiba K.
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1617-22. PubMed ID: 6089668
    [Abstract] [Full Text] [Related]

  • 10. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Antonio S, Isidori P, Gasparini S.
    Anticancer Res; 1994 Aug; 14(5B):2221-7. PubMed ID: 7840527
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 12. Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer.
    Chen YM, Perng RP, Yang KY, Wu HW, Lin WC, Liu JM, Tsai CM, Whang-Peng J.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Aug; 63(8):605-11. PubMed ID: 10969446
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC, McCrystal MR, Christmas TI.
    N Z Med J; 1998 Nov 27; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [Abstract] [Full Text] [Related]

  • 14. Alternating chemotherapy with cyclophosphamide/adriamycin/vincristine (CAV) and cisplatin/etoposide (PVP) against small cell lung cancer. Eastern Shikoku Lung Cancer Chemotherapy Group.
    Bando H, Takishita Y, Ogura T, Sone S, Shimizu E, Nakayama T, Doi H, Kobayashi M.
    Jpn J Clin Oncol; 1991 Dec 27; 21(6):435-9. PubMed ID: 1666660
    [Abstract] [Full Text] [Related]

  • 15. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
    Ohnoshi T, Hiraki S, Ueoka H, Kawahara S, Numata T, Nishii K, Yonei T, Yamashta H, Kiura K, Kozuka A.
    Gan To Kagaku Ryoho; 1989 Apr 27; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
    [Abstract] [Full Text] [Related]

  • 16. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C.
    Lung Cancer; 2005 Jun 27; 48(3):409-13. PubMed ID: 15893010
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
    Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A, Georgoulias V.
    Lung Cancer; 2006 Jul 27; 53(1):59-65. PubMed ID: 16716447
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S, Segawa Y, Harada M.
    Cancer; 1998 Jul 15; 83(2):283-90. PubMed ID: 9669811
    [Abstract] [Full Text] [Related]

  • 19. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K, Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group.
    Clin Cancer Res; 2003 Jan 15; 9(1):143-50. PubMed ID: 12538462
    [Abstract] [Full Text] [Related]

  • 20. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.